Cardiff University says scientists have developed a new anti-cancer stem cell agent capable of targeting aggressive tumour forming cells common to breast, pancreas, colon and prostate cancers.
The new OH14 compound has been licensed by Tiziana Life Sciences, a British-based pharmaceutical company.
It will now undergo further development before undergoing clinical trials. Researchers say studies have shown it to be effective in eliminating a number of different kinds of cancers cells, including cancer stem cells from breast cancer patients.
The breakthrough comes almost exactly a year after the same research team announced that they had discovered a molecule capable of reversing the spread of malignant breast cancer.